Treatment-Emergent Mutations in NAEβ Confer Resistance to the NEDD8-Activating Enzyme Inhibitor MLN4924

Cancer Cell - United States
doi 10.1016/j.ccr.2012.02.009
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

The Nedd8-Activating Enzyme Inhibitor MLN4924 Induces Autophagy and Apoptosis to Suppress Liver Cancer Cell Growth

Cancer Research
Cancer ResearchOncology
2012English

The NEDD8-activating Enzyme Inhibitor MLN4924 Induces DNA Damage in Ph+ Leukemia and Sensitizes for ABL Kinase Inhibitors

Cell Cycle
MedicineDevelopmental BiologyCell BiologyMolecular Biology
2019English

Pevonedistat, a Nedd8-Activating Enzyme Inhibitor, Sensitizes Neoplastic B-Cells to Death Receptor-Mediated Apoptosis

Oncotarget
Oncology
2017English

The N676D and G697R Mutations in the Kinase Domain of FLT3 Confer Resistance to the Inhibitor AC220

Haematologica
Hematology
2012English

Mutations in Ribosomal Protein L10e Confer Resistance to the Fungal-Specific Eukaryotic Elongation Factor 2 Inhibitor Sordarin

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
1999English

Lack of SMALL ACIDIC PROTEIN 1 (SMAP1) Causes Increased Sensitivity to an Inhibitor of RUB/NEDD8-activating Enzyme inArabidopsisseedlings

Plant Signaling & Behavior
2013English

Activity of TAS4464, a Novel NEDD8 Activating Enzyme E1 Inhibitor, Against Multiple Myeloma via Inactivation of NF‐κB Pathways

Cancer Science
Cancer ResearchMedicineOncology
2019English

Profiling the Cross Reactivity of Ubiquitin With the Nedd8 Activating Enzyme by Phage Display

PLoS ONE
Multidisciplinary
2013English

SWI/SNF Mutations Confer Resistance to Ibrutinib Plus Venetoclax in MCL

Cancer Discovery
Oncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy